Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Organogenesis Holdings (ORGO) over the last 9 years, with Q3 2025 value amounting to $63.7 million.

  • Organogenesis Holdings' Cash & Equivalents fell 3243.06% to $63.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.7 million, marking a year-over-year decrease of 3243.06%. This contributed to the annual value of $135.6 million for FY2024, which is 3055.76% up from last year.
  • According to the latest figures from Q3 2025, Organogenesis Holdings' Cash & Equivalents is $63.7 million, which was down 3243.06% from $73.1 million recorded in Q2 2025.
  • Organogenesis Holdings' Cash & Equivalents' 5-year high stood at $135.6 million during Q4 2024, with a 5-year trough of $63.7 million in Q3 2025.
  • Its 5-year average for Cash & Equivalents is $98.7 million, with a median of $100.4 million in 2022.
  • As far as peak fluctuations go, Organogenesis Holdings' Cash & Equivalents soared by 3499.66% in 2021, and later plummeted by 3243.06% in 2025.
  • Quarter analysis of 5 years shows Organogenesis Holdings' Cash & Equivalents stood at $113.9 million in 2021, then dropped by 10.05% to $102.5 million in 2022, then grew by 1.33% to $103.8 million in 2023, then skyrocketed by 30.56% to $135.6 million in 2024, then crashed by 52.98% to $63.7 million in 2025.
  • Its last three reported values are $63.7 million in Q3 2025, $73.1 million for Q2 2025, and $110.0 million during Q1 2025.